Efficacy and Safety of Extended TARPEYO Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropathy
Status:
RECRUITING
Trial end date:
2027-11-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical trial is to assess the efficacy and safety of extended TARPEYO (delayed-release budesonide capsules) treatment in adult patients with primary IgA nephropathy who have completed 9 months of TARPEYO 16 mg once daily treatment in real-world clinical practice. The main question it aims to answer is:
Is there a treatment benefit of TARPEYO 16 mg QD extended use?
Participants will
* take part in this study for about 19 months
* Have urine tests done
* Have blood samples taken
* Have physical examinations done